Ocrelizumab Demonstrates Near-Complete Suppression of Relaps

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

Related Keywords

United States , Colorado , American , Ocrelizumab Ocrevus , Levi Garraway , Scott Newsome , Johns Hopkins University School Of Medicine , National Multiple Sclerosis Society , Global Product Development At Roche , American Academy , Neurology Annual Meeting , Global Product Development , Johns Hopkins University School ,